Skip to main content

Comparison of Standard Initial Dose and Reduced Initial Dose Regorafenib for Colorectal Cancer Patients: A Retrospective Cohort Study

Targeted Oncology volume 14, pages 295–306 (2019)Cite this article

Abstract

Background

The benefit of regorafenib for colorectal cancer patients was demonstrated in previous randomized studies. However, these studies showed a high rate of treatment-related adverse events, and adverse events were more common in Japanese patients. Some studies showed fewer adverse events and a longer survival time with a reduced initial dose. However, the benefits of a reduced initial dose of regorafenib have only been evaluated in small samples.

Objective

Our objective was to analyze the efficacy of initial regorafenib dose reduction compared with a standard dose for colorectal cancer patients.

Patients and methods

We used a hospital-based nationwide claims database. Patients who received regorafenib for metastatic colorectal cancer between June 2013 and July 2017 were included in this study. We divided the patients into a standard initial dose group (standard group) and a reduced initial dose group (reduced group). Overall survival (OS) and adverse events were compared between the two groups. We performed propensity score matching for sensitivity analysis.

Results

We included 2376 patients (1208 in the standard group and 1168 in the reduced group). The median OS was 12.3 months (95% confidence interval (CI): 11.0–13.3) in the standard group and 12.6 months (95% CI: 11.7–13.6) in the reduced group. A log-rank test showed no significant difference between the two groups (p = 0.41). Most adverse events occurred less frequently in the reduced group. In the sensitivity analysis, there was no significant difference for OS.

Conclusions

No significant difference was observed for OS between the standard group and the reduced group. However, there were fewer adverse events in the reduced group. The optimal initial dose of regorafenib should be identified in further studies.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

43,34 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Data Availability

The datasets generated and/or analyzed during the current study are not publicly available due to a contract with Medical Data Vision Co, Ltd. but are available from the corresponding author on reasonable request.

References

  1. Haggar FA, Boushey RP. Colorectal cancer epidemiology: incidence, mortality, survival, and risk factors. Clin Colon Rectal Surg. 2009;22:191–7.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Marley AR, Nan H. Epidemiology of colorectal cancer. Int J Mol Epidemiol Genet. 2016;7:105–14.

    PubMed  PubMed Central  Google Scholar 

  3. Van Cutsem E, Nordlinger B, Cervantes A. Advanced colorectal cancer: ESMO Clinical Practice Guidelines for treatment. Ann Oncol. 2010;21:93–7.

    Article  Google Scholar 

  4. Watanabe T, Muro K, Ajioka Y, Hashiguchi Y, Ito Y, Saito Y, et al. Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer. Int J Clin Oncol. 2018;23:1–34.

    Article  PubMed  Google Scholar 

  5. Benson AB 3rd, Bekaii-Saab T, Chan E, Chen YJ, Choti MA, Cooper HS, et al. Metastatic colon cancer, version 3.2013: featured updates to the NCCN Guidelines. J Natl Compr Canc Netw. 2013;11:141–52.

    Article  CAS  PubMed  Google Scholar 

  6. Grothey A, Cutsem EV, Sobrero A, Siena S, Falcone A, Ychou M, et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013;381:303–12.

    Article  CAS  PubMed  Google Scholar 

  7. Xu R, Yau CC, Li J, Qin S, Xu R, Yau TCC, et al. Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2015;16:619–29.

    Article  CAS  PubMed  Google Scholar 

  8. Yoshino T, Komatsu Y, Yamada Y, Yamazaki K, Tsuji A, Ura T, et al. Randomized phase III trial of regorafenib in metastatic colorectal cancer: analysis of the CORRECT Japanese and non-Japanese subpopulations. Invest New Drugs. 2015;33:740–50.

    Article  CAS  PubMed  Google Scholar 

  9. Ben-Ami E, Barysauskas CM, von Mehren M, Heinrich MC, Corless CL, Butrynski JE, et al. Long-term follow-up results of the multicenter phase II trial of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of standard tyrosine kinase inhibitor therapy. Ann Oncol. 2016;27:1794–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Bekaii-Saab TS, Ou F-S, Anderson DM, Ahn DH, Boland PM, Ciombor KK, et al. Regorafenib dose optimization study (ReDOS): randomized phase II trial to evaluate dosing strategies for regorafenib in refractory metastatic colorectal cancer (mCRC)-An ACCRU Network study. J Clin Oncol. 2018;36(suupl_4):611.

    Article  Google Scholar 

  11. Hirano G, Makiyama A, Makiyama C, Esaki T, Oda H, Uchino K, et al. Reduced dose of salvage-line regorafenib monotherapy for metastatic colorectal cancer in Japan. Anticancer Res. 2015;35:371–7.

    CAS  PubMed  Google Scholar 

  12. Yamaguchi K, Komatsu Y, Satoh T, Uetake H, Yoshino T, Nishida T, et al. Large-scale, prospective observavtional study of regorafenib in Japanese patients with metastatic colorectal cancer in a real-world clinical setting. Oncologist. 2019. https://doi.org/10.1634/theoncologist.2018-0377.

    Article  PubMed  Google Scholar 

  13. Osawa H. Response to regorafenib at an initial dose of 120 mg as salvage therapy for metastatic colorectal cancer. Mol Clin Oncol. 2017;5:365–72.

    Article  CAS  Google Scholar 

  14. Kudo T, Kato T, Kagawa Y, Sakai D, Satoh T, Doki Y, et al. Phase II dose titration study of regorafenib for patients with unresectable metastatic colorectal cancer that progressed after standard chemmotherapy. J Clin Oncol. 2018;36(suppl_4):821.

    Article  Google Scholar 

  15. Vandenbroucke JP, von Elm E, Altman DG, Gotzsche PC, Mulrow CD, Pocock SJ, et al. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. Epidemiology. 2007;18:805–35.

    Article  PubMed  Google Scholar 

  16. Urushihara H, Taketsuna M, Liu Y, Oda E, Nakamura M, Nishiuma S, et al. Increased risk of acute pancreatitis in patients with type 2 diabetes: an observational study using a Japanese hospital database. PLoS One. 2012;7(12):e53224.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Tanaka S, Seto K, Kawakami K. Pharmacoepidemiology in Japan: medical databases and research achievements. J Pharm Health Care Sci. 2015;1:16.

    Article  PubMed  PubMed Central  Google Scholar 

  18. Mross K, Frost A, Steinbild S, Hedbom S, Buchert M, Fasol U, et al. A phase I dose-escalation study of regorafenib (BAY 73-4506), an inhibitor of oncogenic, angiogenic, and stromal kinases, in patients with advanced solid tumors. Clin Cancer Res. 2012;18:2658–67.

    Article  CAS  PubMed  Google Scholar 

  19. Sunakawa Y, Furuse J, Okusaka T, Ikeda M, Nagashima F, Ueno H, et al. Regorafenib in Japanese patients with solid tumors: phase I study of safety, efficacy, and pharmacokinetics. Invest New Drugs. 2014;32:104–12.

    Article  CAS  PubMed  Google Scholar 

  20. Rubin DB, Thomas N. Matching using estimated propensity scores: relating theory to practice. Biometrics. 1996;52:249–64.

    Article  CAS  PubMed  Google Scholar 

  21. Moriwaki T, Fukuoka S, Taniguchi H, Takashima A, Kumekawa Y, Kajiwara T, et al. Propensity score analysis of regorafenib versus trifluridine/tipiracil in patients with metastatic colorectal cancer refractory to standard chemotherapy (REGOTAS): A Japanese Society for Cancer of the Colon and Rectum Multicenter Observational Study. Oncologist. 2018;23:7–15.

    Article  CAS  PubMed  Google Scholar 

  22. Grothey A, George S, van Cutsem E, Blay J-Y, Sobrero A, Demetri GD. Optimizing treatment outcomes with regorafenib: personalized dosing and other strategies to support patient care. Oncologist. 2014;19:669–80.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Komatsu Y, Muro K, Yamaguchi K, Satoh T, Uetake H, Yoshino T, et al. Safety and efficacy of regorafenib post-marketing surveillance (PMS) in Japanese patients with metastatic colorectal cancer (mCRC). J Clin Oncol. 2017;35:721.

    Article  Google Scholar 

  24. Adenis A, de la Fouchardiere C, Paule B, Burtin P, Tougeron D, Wallet J, et al. Survival, safety, and prognostic factors for outcome with Regorafenib in patients with metastatic colorectal cancer refractory to standard therapies: results from a multicenter study (REBECCA) nested within a compassionate use program. BMC Cancer. 2016;16:412.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Masuishi T, Taniguchi H, Hamauchi S, Komori A, Kito Y, Narita Y, et al. Regorafenib versus trifluridine/tipiracil for refractory metastatic colorectal cancer: a retrospective comparison. Clin Colorectal Cancer. 2016;16:12–22.

    Google Scholar 

  26. Van Cutsem E, Martinelli E, Cascinu S, Sobrero A, Banzi M, Seitz JF, et al. Regorafenib for patients with metastatic colorectal cancer who progressed after standard therapy: results of the large, single-arm. Open-label Phase IIIb CONSIGN study. Oncologist. 2019;24(2):185–92.

    Article  CAS  PubMed  Google Scholar 

  27. Strumberg D, Scheulen ME, Schultheis B, Richly H, Frost A, Büchert M, et al. Regorafenib (BAY 73-4506) in advanced colorectal cancer: a phase I study. Br J Cancer. 2012;106:1722–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

We thank Dr. Masato Takeuchi for advice on the revised manuscript.

Author information

Affiliations

  1. Department of Pharmacoepidemiology, Graduate School of Medicine and Public Health, Kyoto University, Yoshida-konoecho, Sakyo-ku, Kyoto, 606-8501, Japan

    Masayuki Nakashima, Kazuki Ide & Koji Kawakami

  2. Center for the Promotion of Interdisciplinary Education and Research, Kyoto University, Yoshida-konoecho, Sakyo-ku, Kyoto, 606-8501, Japan

    Kazuki Ide & Koji Kawakami

Authors
  1. Masayuki Nakashima
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kazuki Ide
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Koji Kawakami
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Koji Kawakami.

Ethics declarations

Funding

No external funding was used in the preparation of this manuscript.

Conflict of interest

Koji Kawakami receives honoraria from Shin Nippon Biomedical Laboratories, LTD.; research funds from: Olympus Corporation, Sumitomo Dainippon Pharma Co., Ltd., Bayer Yakuhin Ltd., Stella Pharma Corporation, Novartis Pharma K.K., CMIC Co., Ltd., Amgen Astellas BioPharma K.K., Suntory Beverage & Food Ltd., Medical Platform Co., Ltd.; and holds stocks of: School Health Record Center Co., Ltd. and Real World Data, Co., Ltd. There are no patent products under development or marketed products to declare, relevant to those companies. Masayuki Nakashima and Kazuki Ide declare that they have no conflicts of interest that might be relevant to the contents of this manuscript.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (PDF 74 kb)

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Nakashima, M., Ide, K. & Kawakami, K. Comparison of Standard Initial Dose and Reduced Initial Dose Regorafenib for Colorectal Cancer Patients: A Retrospective Cohort Study. Targ Oncol 14, 295–306 (2019). https://doi.org/10.1007/s11523-019-00642-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11523-019-00642-8